FDA-approved1,2,3,5,7,9Evidence: Limited human dataSexual and reproductive health · Cancer

Leuprolide1

Also called Leuprolide acetate, Lupron, Eligard, Vobrig1,2,5,7

Key takeaway

Leuprolide is a lab-made version of gonadotropin-releasing hormone (GnRH) that, after an initial rise, suppresses the body’s production of testosterone and estrogen.1 It has been FDA-approved since 1985 and is sold under several names, including Lupron, Lupron Depot, Eligard and Fensolvi. The label cited here is Eligard’s, which covers advanced prostate cancer.1,2,3,5,6 On August 26, 2026, FDA approved another leuprolide product, Vobrig, for central precocious puberty in children.7,9

Leuprolide at a glance

What it isA GnRH agonist. The Eligard label describes leuprolide acetate as a synthetic nonapeptide analogue of GnRH that is more potent than the natural hormone.1
FDA statusFDA-approved. Drugs@FDA lists Lupron with an original approval date of April 9, 1985, and Eligard with one of January 23, 2002, among many leuprolide applications. The cited Eligard label has no boxed warning.1,2,5
Human evidenceFour open-label studies described in the Eligard label, which measured whether testosterone fell to castrate levels in men with prostate cancer.1
Evidence strengthLimited human data. The only cited human studies are small, short, uncontrolled, or incompletely reported, such as case series, pilot studies, or trials published only as a conference abstract whose methods and results cannot be checked. How this label is assigned

What is leuprolide?

Leuprolide is a lab-made peptide of nine amino acids modelled on gonadotropin-releasing hormone (GnRH). The Eligard label states that it is more potent than the natural hormone.1

Drugs@FDA lists many leuprolide applications, including Lupron (1985), Lupron Depot (1989), Lupron Depot-Ped (1993), Eligard (2002), Fensolvi (2020) and Vobrig (2026).2,3,4,5,6,9

How does leuprolide work?

The label states that leuprolide acts as an inhibitor of gonadotropin secretion when given continuously: after an initial stimulation, it suppresses the production of sex hormones by the testes and ovaries, an effect that is reversible when treatment stops.1

According to the label, testosterone first rises and then falls to the range seen in surgically castrated men about three weeks after treatment starts.1

What do human studies show?

The Eligard label describes four open-label studies in men with prostate cancer, one for each of its formulations, with 120, 117, 90 and 111 participants. The main measure was whether testosterone fell to castrate levels and stayed there.1

At the end of each study, 99% to 100% of the men evaluated had testosterone at castrate levels, and prostate-specific antigen (PSA) fell in every man whose level was raised at the start, according to the label.1

The label reports hormone and PSA results from these studies; it does not report survival or cancer progression.1

Leuprolide was also the comparison treatment in HERO, a randomized trial of another drug, relugolix, in 930 men with advanced prostate cancer. Sustained testosterone suppression was reported in 88.8% of the leuprolide group and 96.7% of the relugolix group.8

What the evidence base contains

  • Small, short, or incompletely reported human study Four open-label studies described in the Eligard label, one for each of its formulations, in 120, 117, 90 and 111 men with prostate cancer, with suppression of testosterone to castrate levels as the main measure.1

Evidence-strength label: Limited human data. How this label is assigned

Is leuprolide FDA-approved?

Yes. Drugs@FDA lists Lupron, application NDA019010, with an original approval date of April 9, 1985, followed by Lupron Depot on January 26, 1989, Lupron Depot-Ped on April 16, 1993, Eligard (NDA021343) on January 23, 2002 and Fensolvi on May 1, 2020.2,3,4,5,6

The Eligard label cited here (DailyMed SPL version 19, published May 11, 2026) states that it is indicated for the treatment of advanced prostate cancer. Other leuprolide products carry their own labels and uses.1

That label has no boxed warning. It states that Eligard is contraindicated in people allergic to GnRH, GnRH agonists or any of its components.1

Its warnings cover a temporary worsening of prostate cancer symptoms when testosterone first rises, including cases of urinary blockage and spinal cord compression; high blood sugar and diabetes; heart attack, sudden cardiac death and stroke reported with GnRH agonists in men; changes in heart rhythm; convulsions; severe skin reactions; and possible harm to a fetus.1

On August 26, 2026, FDA approved Vobrig (leuprolide acetate), from Sun Pharmaceutical Industries, for the treatment of central precocious puberty in children, according to the approval letter. Drugs@FDA lists its application, NDA213225, with that original approval date.7,9

Timeline

  1. FDA approves Lupron, the first leuprolide product, according to Drugs@FDA.2
  2. FDA approves Lupron Depot, according to Drugs@FDA.3
  3. FDA approves Eligard, according to Drugs@FDA.5
  4. Results of the HERO trial, with leuprolide as the comparison treatment, are published.8
  5. FDA approves Fensolvi, according to Drugs@FDA.6
  6. DailyMed publishes the Eligard label version cited on this page.1
  7. FDA approves Vobrig for central precocious puberty in children.7,9

What is still unknown?

How the Eligard label’s findings apply to other leuprolide products, which have their own labels and approved uses.1,3,7

How leuprolide affects survival compared with other treatments: the label’s studies were open-label and report testosterone and PSA, and HERO measured testosterone suppression rather than survival.1,8

PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.

Go deeper

Records, reviews and history

Everything PeptideScanner has collected for Leuprolide: reviews, official-source readings, registry and literature records, and every change to this profile.

What the trial and literature lists cover. The trials and papers listed for Leuprolide are the records PeptideScanner has selected and published, not every registration or paper about Leuprolide. A daily check adds newly updated registrations and newly indexed papers that pass the publication checks. How records are selected.

Status brief and reviewed-evidence summary

Evidence summary

What the cited records show

What is its status in the cited records?

FDA-approved as Lupron, Eligard, Vobrig and other leuprolide products. The cited Eligard label describes four open-label studies that measured testosterone suppression in men with prostate cancer. Each leuprolide product has its own label and uses.↗↗↗↗↗↗

Status sources checked through August 14, 2026. See status sources and coverage →

What do the reviewed human studies say?

Human evidence reviewed September 20, 2026 · Review version 2.

Review source snapshots checked September 20, 2026 · Integrity checked September 20, 2026.

A bounded review of two randomized comparisons involving leuprolide: one pelvic-pain trial and one androgen-deprivation trial using leuprolide as the active comparator.↗↗

What the reviewed sources report

In the reviewed pelvic-pain trial, both treatment groups improved without a significant between-group difference. In the prostate-cancer trial, the oral comparator produced more sustained testosterone suppression than leuprolide; that biochemical endpoint does not establish a difference in cancer survival.↗↗

What remains unresolved?

  • How do the compared approaches affect long-term patient-important outcomes, harms, and treatment persistence beyond the reviewed follow-up windows?↗↗

Read study designs, results, limitations, and sources →

What does the U.S. product label say?

Eligard · Read November 15, 2026 · Preserved label summary 2

Which population and use does the label cover?

The cited Eligard label covers the treatment of advanced prostate cancer. Other leuprolide products, including those for central precocious puberty, carry their own labels and uses. Label: 1 ↗

Which safety limits matter?

The label contraindicates hypersensitivity to GnRH, GnRH agonist analogues or the product's components. Its warnings address tumor flare when testosterone first rises, hyperglycemia and diabetes, cardiovascular events reported with GnRH agonists in men, QT prolongation, convulsions, severe cutaneous adverse reactions and embryo-fetal toxicity. Label: 4, 5 ↗

Label edition and source pins

U.S. product labeling hosted by the National Library of Medicine. This account concerns this product and label edition; other formulations and jurisdictions require their own records.

ELIGARD (leuprolide acetate) injection, suspension, extended release · SPL version 19 · published 2026-05-11

Label ZIP SHA-256: e08a1c26251d2db47180407faaf2e74660c8798bec8fce2d22c67face8e7904b. Extracted XML SHA-256: cad52f6c3659afbf8c4280f11330ea352a27110cbb2f87020c76d469dd1b8b96.

Open versioned label context data →

Reviews summarize selected studies; their scope and limitations are shown above.

Read the full Human Evidence Review

Supervised synthesis

What do selected human studies report about Leuprolide?

Manually reviewed September 20, 2026 · version 2

Browse all Human Evidence Reviews · Open preserved synthesis version 2 →

A bounded review of two randomized comparisons involving leuprolide: one pelvic-pain trial and one androgen-deprivation trial using leuprolide as the active comparator.12

Bottom line from this bounded source set

In the reviewed pelvic-pain trial, both treatment groups improved without a significant between-group difference. In the prostate-cancer trial, the oral comparator produced more sustained testosterone suppression than leuprolide; that biochemical endpoint does not establish a difference in cancer survival.12

Reviewed study record

Endometriosis-associated pelvic-pain trial

Design

A prospective, randomized, double-blind controlled trial compared leuprolide with continuous oral contraceptives over 48 weeks.1

Population

The trial enrolled 47 women with endometriosis-associated pelvic pain at academic medical centers in two U.S. cities.1

Outcomes reported

Pain and depression scores declined significantly from baseline in both groups, while the reported reductions did not differ significantly between groups.1

Limitations

The trial was small, and improvement within each group does not establish that the treatments were equivalent across broader populations or longer follow-up.1

Reviewed study record

HERO androgen-deprivation trial

Design

A sponsor-funded, randomized Phase 3 trial compared oral relugolix with leuprolide for 48 weeks; sustained testosterone suppression was the primary endpoint.2

Population

The report describes 930 men with advanced prostate cancer who received treatment: 622 received relugolix and 308 received leuprolide. These are treated-participant counts, not a stated count of everyone randomized.2

Outcomes reported

Sustained testosterone suppression was reported for 96.7% of the relugolix group and 88.8% of the leuprolide group, meeting the trial's noninferiority and superiority criteria for that endpoint.2

Limitations

Leuprolide was the comparator, not the experimental treatment, and the primary result concerned testosterone suppression rather than cancer progression or survival.2

Reviewed source set

  1. PubMed · 21300339Randomized trial of leuprolide versus continuous oral contraceptives in the treatment of endometriosis-associated pelvic pain ↗PubMed PMID 21300339 · EFetch XML reviewed 2026-09-20 · payload SHA-256 acdc72872e6bd7de45be01788dfd401b16780ce2ac46cd3834a9299cbf8314c3
    No registered Crossref update in the reviewed snapshotChecked September 20, 2026 for DOI 10.1016/j.fertnstert.2011.01.027. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
  2. PubMed · 32469183Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer ↗PubMed PMID 32469183 · EFetch XML reviewed 2026-09-20 · payload SHA-256 ff23e8f570d660744b13fbe1420af8f24b062e1dad2ce2b36eee4e240dd2a36b
    No registered Crossref update in the reviewed snapshotChecked September 20, 2026 for DOI 10.1056/nejmoa2004325. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
Official-source readings

Inside the official reviews

Reviewed 2026-09-19 · Preserved version 1

This application relied on a formulation-specific bridge

FDA’s Camcevi review describes a 505(b)(2) application relying in part on prior findings for Lupron, with supporting clinical bridging data. It is not a new trial of every leuprolide formulation or indication. FDA PDF pp. 13 ↗

More findings, study links and document coverage

The pivotal study was uncontrolled

The reviewed trial enrolled 137 patients with advanced prostate cancer in a single-arm, open-label design. Without a randomized comparator, it cannot establish superiority over other androgen-deprivation treatments. FDA PDF pp. 13 ↗

Testosterone suppression was the primary endpoint

FDA evaluated whether testosterone suppression was achieved and maintained from day 28 through day 336. That endpoint is distinct from demonstrating longer survival or better patient-reported quality of life in this trial. FDA PDF pp. 13, 18 ↗

The extension was a smaller safety follow-up

An additional 30 patients continued into the safety extension after day 336. They should not be counted as an independent confirmatory trial or as long-term observations for all original participants. FDA PDF pp. 13 ↗

Read the separate U.S. label account → Label version and indication scope are preserved there; these agency reviews describe their own dated evidence.

Document coverage

Selected sections read in 1 of 1 inventoried documents; 0 not yet reviewed. Reading selected sections does not establish complete appraisal of a document.

One selected official document from the retained EMA document inventory or an independently retrieved FDA application package. Other formulations, later variations, national records and the wider source inventory remain outside this reading. EMA inventory source ↗

Inspect documents, application identities and source pins

Page references use one-based PDF file pages, which can differ from printed page numbers. Candidate feed associations are not verified application identities.

  • Camcevi: FDA selected application review ↗

    Selected sections reviewed · fda-leuprolide-review-2021 · Document/feed date: 2021-05-12

    Application identity and document date were checked in the PDF, independently of the URL year or candidate feed association.

    Verified: Camcevi · NDA 211488 · Document dated 2021-05-12. Identity checked on PDF pp. 2.

    Selected identity, clinical-summary and benefit-risk sections only; this is not a full-document or all-indication appraisal.

    Retrieved 2026-09-19. Read PDF pages: 2, 13, 18 of 167. SHA-256: d115a3d1c53c53ff80dfe0b6f5cd9f6caa5d963733f45199d78bb049105f5db4.

Remaining work

  • Review other leuprolide formulations and indications separately from Camcevi.
  • Reconcile the pivotal protocol, publication and longer follow-up before making patient-centered outcome claims.

Open versioned document coverage and study pins →

European medicine records · 1 products or applications

EMA medicine metadata checked 2026-09-15. These are product-specific centralized records; national European authorizations and full product-information assessments require separate coverage.

Application withdrawal and refusal are distinct from marketing authorization. A withdrawal status alone does not establish why it occurred. These metadata entries do not substitute for indication, population or safety details in the relevant product information.

Open versioned records and source-feed pins →

Research coverage and study families

Search and screening record checked 2026-09-15. Counts describe records, not independent trials. Full-text appraisal is separate from an abstract review.

Open machine-readable coverage and record decisions →

PubMed search

Catalog-name and calibrated alias discovery for human evidence review. Complete query retrieval is separate from clinical eligibility, study-family linkage and appraisal.

2971 retrieved · 2 included · 0 excluded · 2969 awaiting a decision · 0 full-text appraisals

Search terms, record decisions and remaining work

"Leuprolide"[Title/Abstract] OR "leuprorelin"[Title/Abstract] OR "Leuprolide acetate"[Title/Abstract]

Source retrievals and payload pins
  • Open the source endpoint ↗

    Retrieved 2026-09-15T11:09:38.867039+00:00 · HTTP 200 · SHA-256 a2c7525dc783bc2ad099df797c48514bdca4acf81cfeda16c7415ecd43ceb21c.

  • Retrieved IDs completely represent this query response, not all relevant literature. Additional aliases, references and non-PubMed sources require separate searches.
  • Unscreened records may include animal or cell experiments, reviews, secondary analyses, mixtures, protocols and unrelated name matches.
  • Study-family mappings use available declared registry IDs; unresolved mappings do not create independent trial counts. Full-text, corrections and registry comparison remain separate work.

Showing 25 of 2971 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

  1. PubMed 32469183 — include: Selected published human report; abstract reviewed. Full-text and study-family appraisal remain separate. Study families: NCT03085095.
    Bibliographic record recheck · 2026-09-15

    The selected PubMed XML payload matches the previous reviewed snapshot. This is a metadata recheck, not a new appraisal or a finding that no corrections exist. Open PubMed record ↗

    SHA-256 ff23e8f570d660744b13fbe1420af8f24b062e1dad2ce2b36eee4e240dd2a36b.

  2. PubMed 21300339 — include: Selected published human report; abstract reviewed. Full-text and study-family appraisal remain separate. Study families: leuprolide-PMID21300339-registry-linkage-unresolved.
    Bibliographic record recheck · 2026-09-15

    The selected PubMed XML payload matches the previous reviewed snapshot. This is a metadata recheck, not a new appraisal or a finding that no corrections exist. Open PubMed record ↗

    SHA-256 acdc72872e6bd7de45be01788dfd401b16780ce2ac46cd3834a9299cbf8314c3.

  3. PubMed 42728640 — not screened: Name-query match awaiting clinical eligibility screening.
  4. PubMed 42719229 — not screened: Name-query match awaiting clinical eligibility screening.
  5. PubMed 42713047 — not screened: Name-query match awaiting clinical eligibility screening.
  6. PubMed 42708086 — not screened: Name-query match awaiting clinical eligibility screening.
  7. PubMed 42700293 — not screened: Name-query match awaiting clinical eligibility screening.
  8. PubMed 42685950 — not screened: Name-query match awaiting clinical eligibility screening.
  9. PubMed 42682049 — not screened: Name-query match awaiting clinical eligibility screening.
  10. PubMed 42617170 — not screened: Name-query match awaiting clinical eligibility screening.
  11. PubMed 42615454 — not screened: Name-query match awaiting clinical eligibility screening.
  12. PubMed 42615451 — not screened: Name-query match awaiting clinical eligibility screening.
  13. PubMed 42613861 — not screened: Name-query match awaiting clinical eligibility screening.
  14. PubMed 42591741 — not screened: Name-query match awaiting clinical eligibility screening.
  15. PubMed 42574969 — not screened: Name-query match awaiting clinical eligibility screening.
  16. PubMed 42529459 — not screened: Name-query match awaiting clinical eligibility screening.
  17. PubMed 42469731 — not screened: Name-query match awaiting clinical eligibility screening.
  18. PubMed 42427703 — not screened: Name-query match awaiting clinical eligibility screening.
  19. PubMed 42423152 — not screened: Name-query match awaiting clinical eligibility screening.
  20. PubMed 42421559 — not screened: Name-query match awaiting clinical eligibility screening.
  21. PubMed 42415823 — not screened: Name-query match awaiting clinical eligibility screening.
  22. PubMed 42406777 — not screened: Name-query match awaiting clinical eligibility screening.
  23. PubMed 42399824 — not screened: Name-query match awaiting clinical eligibility screening.
  24. PubMed 42388856 — not screened: Name-query match awaiting clinical eligibility screening.
  25. PubMed 42369946 — not screened: Name-query match awaiting clinical eligibility screening.

FDA search

Active-ingredient name query in openFDA Drugs@FDA. Returned application identities include salt forms and combination products; exact indications, approval conditions, supplements and marketing status require document-level review.

28 retrieved · 28 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals

Search terms, record decisions and remaining work

products.active_ingredients.name:"LEUPROLIDE"

Source retrievals and payload pins
  • Open the source endpoint ↗

    Retrieved 2026-09-15T11:10:18.395473+00:00 · HTTP 200 · SHA-256 fd6df635088f903d264f8807c125726ec88e89adce01f0bcd0e1bb0b3da39f61.

  • Zero results describe this query response only, not absence of FDA approval or worldwide nonapproval.
  • This endpoint does not inventory every label, advisory proceeding, safety communication or regulatory document. Application inclusion does not establish current marketing or approval of every use.

Showing 25 of 28 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

  1. FDA ANDA213829 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: LEUPROLIDE ACETATE.
  2. FDA NDA205054 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: LEUPROLIDE ACETATE.
  3. FDA ANDA075471 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: LEUPROLIDE ACETATE.
  4. FDA NDA021731 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: LEUPROLIDE ACETATE.
  5. FDA NDA021379 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: LEUPROLIDE ACETATE.
  6. FDA ANDA078885 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: LEUPROLIDE ACETATE.
  7. FDA NDA021088 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: LEUPROLIDE ACETATE.
  8. FDA NDA213150 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: LEUPROLIDE ACETATE.
  9. FDA NDA020263 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: LEUPROLIDE ACETATE.
  10. FDA NDA203696 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: LEUPROLIDE ACETATE, NORETHINDRONE ACETATE.
  11. FDA NDA019732 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: LEUPROLIDE ACETATE.
  12. FDA NDA219745 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: LEUPROLIDE MESYLATE.
  13. FDA NDA213225 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: LEUPROLIDE ACETATE.
  14. FDA NDA021488 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: LEUPROLIDE ACETATE.
  15. FDA NDA211488 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: LEUPROLIDE MESYLATE.
  16. FDA NDA020011 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: LEUPROLIDE ACETATE.
  17. FDA ANDA217437 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: LEUPROLIDE ACETATE.
  18. FDA ANDA215336 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: LEUPROLIDE ACETATE.
  19. FDA ANDA074728 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: LEUPROLIDE ACETATE.
  20. FDA ANDA212963 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: LEUPROLIDE ACETATE.
  21. FDA NDA019010 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: LEUPROLIDE ACETATE.
  22. FDA NDA019943 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: LEUPROLIDE ACETATE.
  23. FDA ANDA215826 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: LEUPROLIDE ACETATE.
  24. FDA NDA020517 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: LEUPROLIDE ACETATE.
  25. FDA NDA020708 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: LEUPROLIDE ACETATE.

EMA search

Local matching in the pinned EMA medicines feed; document matches also use identified EMA product numbers. This is not every national European record.

1 retrieved · 1 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals

Search terms, record decisions and remaining work

Case-insensitive word-boundary identity terms: ["Leuprolide", "Leuprolide acetate", "leuprorelin"]

Source retrievals and payload pins
  • Open the source endpoint ↗

    Retrieved 2026-09-15T08:34:22.905972+00:00 · HTTP 200 · SHA-256 a947c2b8a56ac2b92ec96156843f262f5e516f83b375d6791d67a8f6dc695729.

  • Document appraisal and national European sources remain open.
  • Zero matches apply only to these feed fields and terms; orphan designation is not approval.

Showing 1 of 1 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

  1. EMA EMEA/H/C/005034 — include: EMA feed product Camcevi; reported status: Authorised. Exact indication and decision documents remain unappraised.

EMA search

Local matching in the pinned EMA documents feed; document matches also use identified EMA product numbers. This is not every national European record.

29 retrieved · 9 included · 0 excluded · 20 awaiting a decision · 0 full-text appraisals

Search terms, record decisions and remaining work

Case-insensitive word-boundary identity terms: ["Leuprolide", "Leuprolide acetate", "leuprorelin"]

Source retrievals and payload pins
  • Open the source endpoint ↗

    Retrieved 2026-09-15T08:34:29.167460+00:00 · HTTP 200 · SHA-256 c0c68d7d77783e0355cbc75bdd04772e9acc163236fc68abcd794477c4c3d439.

  • Document appraisal and national European sources remain open.
  • Zero matches apply only to these feed fields and terms; orphan designation is not approval.

Showing 25 of 29 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

  1. EMA 55292 — include: Document linked by EMA product number; content unappraised. Camcevi : EPAR - Medicine overview
  2. EMA 55296 — include: Document linked by EMA product number; content unappraised. Camcevi : EPAR - Public Assessment Report
  3. EMA 63485 — include: Document linked by EMA product number; content unappraised. Camcevi-H-C-PSUSA-00010877-202307 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation
  4. EMA 58657 — include: Document linked by EMA product number; content unappraised. Camcevi : EPAR - Procedural steps taken and scientific information after authorisation (archive)
  5. EMA 67619 — include: Document linked by EMA product number; content unappraised. Camcevi : EPAR - Procedural steps taken and scientific information after authorisation
  6. EMA 73706 — include: Document linked by EMA product number; content unappraised. Camcevi-X-0000258054 : EPAR - Assessment report - Variation
  7. EMA 55297 — include: Document linked by EMA product number; content unappraised. Camcevi : EPAR - Risk management plan
  8. EMA 55294 — include: Document linked by EMA product number; content unappraised. Camcevi : EPAR - All Authorised Presentations
  9. EMA 55293 — include: Document linked by EMA product number; content unappraised. Camcevi : EPAR - Product Information
  10. EMA 4034 — not screened: Title-name match awaiting identity and document review. Leuprorelin: List of nationally authorised medicinal products - PSUSA/00001844/201707
  11. EMA 5467 — not screened: Title-name match awaiting identity and document review. EU/3/16/1821: Public summary of opinion on orphan designation: Leuprorelin acetate for the treatment of congenital hypogonadotropic hypogonadism
  12. EMA 16609 — not screened: Title-name match awaiting identity and document review. Leuprorelin: CMDh scientific conclusions and grounds for variation, amendments to the product information and timetable for the implementation - PSUSA/00001844/201707
  13. EMA 44708 — not screened: Title-name match awaiting identity and document review. Leuprorelin-containing depot medicines Article-31 referral - Review of handling errors with depot formulations of leuprorelin medicines started
  14. EMA 44709 — not screened: Title-name match awaiting identity and document review. Leuprorelin-containing depot medicines Article-31 referral - Notification
  15. EMA 44711 — not screened: Title-name match awaiting identity and document review. Leuprorelin-containing depot medicines Article-31 referral - Annex I
  16. EMA 44712 — not screened: Title-name match awaiting identity and document review. Leuprorelin-containing depot medicines Article-31 referral - List of questions
  17. EMA 47674 — not screened: Title-name match awaiting identity and document review. Leuprorelin-containing depot medicines Article-31 referral - PRAC recommends new measures to avoid handling errors
  18. EMA 47675 — not screened: Title-name match awaiting identity and document review. Leuprorelin depot medicines: PRAC recommends new measures to avoid handling errors
  19. EMA 48131 — not screened: Title-name match awaiting identity and document review. Leuprorelin-containing depot medicines Article-31 referral - New measures to avoid handling errors with leuprorelin depot medicines
  20. EMA 48132 — not screened: Title-name match awaiting identity and document review. Leuprorelin-containing depot medicines Article-31 referral - Annex III
  21. EMA 48133 — not screened: Title-name match awaiting identity and document review. Leuprorelin-containing depot medicines Article-31 referral - Timetable for the implementation of the CMDh position (Annex V)
  22. EMA 48134 — not screened: Title-name match awaiting identity and document review. Leuprorelin-containing depot medicinal products: new measures to avoid handling errors with leuprorelin depot medicines
  23. EMA 48468 — not screened: Title-name match awaiting identity and document review. Leuprorelin-containing depot medicines Article-31 referral - Public assessment report to PRAC recommendation
  24. EMA 48520 — not screened: Title-name match awaiting identity and document review. Leuprorelin-containing depot medicines Article-31 referral - Annex II
  25. EMA 48521 — not screened: Title-name match awaiting identity and document review. Leuprorelin-containing depot medicines Article-31 referral - Annex IV

EMA search

Local matching in the pinned EMA orphans feed; document matches also use identified EMA product numbers. This is not every national European record.

1 retrieved · 1 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals

Search terms, record decisions and remaining work

Case-insensitive word-boundary identity terms: ["Leuprolide", "Leuprolide acetate", "leuprorelin"]

Source retrievals and payload pins
  • Open the source endpoint ↗

    Retrieved 2026-09-15T08:34:31.262344+00:00 · HTTP 200 · SHA-256 7448bf4e77e3345b3f3fbb7062c335d2302d8ea458a246bbe8256ce48aad2806.

  • Document appraisal and national European sources remain open.
  • Zero matches apply only to these feed fields and terms; orphan designation is not approval.

Showing 1 of 1 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

  1. EMA EU/3/16/1821 — include: EMA orphan feed identifies leuprorelin acetate; designation status: Positive. Orphan designation is not marketing authorization.

ClinicalTrials.gov search

ClinicalTrials.gov name/alias discovery, including cited product names. Matches may concern combinations, background references or different formulations; identity and outcomes need screening.

544 retrieved · 0 included · 0 excluded · 544 awaiting a decision · 0 full-text appraisals

Search terms, record decisions and remaining work

"Leuprolide" OR "Leuprolide acetate" OR "leuprorelin" OR "Camcevi"

Source retrievals and payload pins
  • Open the source endpoint ↗

    Retrieved 2026-09-15T11:26:19.713059+00:00 · HTTP 200 · SHA-256 ec374fa28a9f949abdcce33588c564adda3bd47fde67ebac0061e33c6fe18c7f.

  • Open the source endpoint ↗

    Retrieved 2026-09-15T11:26:21.040601+00:00 · HTTP 200 · SHA-256 cc84516a25e3bae14b51f0911cc3a1d2ca94f623fedee6898578157056fef8d4.

  • Open the source endpoint ↗

    Retrieved 2026-09-15T11:26:22.423857+00:00 · HTTP 200 · SHA-256 6138a1ad186f1feeb48a13291c85bff960f6fcf9656fc072f9457fe4f52a0993.

  • Open the source endpoint ↗

    Retrieved 2026-09-15T11:26:23.820317+00:00 · HTTP 200 · SHA-256 54990cacba001ddccf9edd5a895b11925ce1479c85deb1c1fb1d6b9503eff77e.

  • Open the source endpoint ↗

    Retrieved 2026-09-15T11:26:25.122831+00:00 · HTTP 200 · SHA-256 63f75c53bea461b2e384d643ba70bb9af8c1ac21f660cac735e8cd7e688aa9d2.

  • Open the source endpoint ↗

    Retrieved 2026-09-15T11:26:26.355748+00:00 · HTTP 200 · SHA-256 631fd79e7a94d1c6dd755cc9bb4e5b98ffe4677bef8d7335a3df1678c533405c.

  • Registration is not evidence that a study succeeded, that results were published, or that a use is approved.
  • Other registries, unregistered studies and additional aliases remain outside this query.

Showing 25 of 544 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

  1. ClinicalTrials.gov NCT02023463 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
  2. ClinicalTrials.gov NCT03573648 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
  3. ClinicalTrials.gov NCT03396978 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
  4. ClinicalTrials.gov NCT03263299 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
  5. ClinicalTrials.gov NCT06106932 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
  6. ClinicalTrials.gov NCT00220350 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
  7. ClinicalTrials.gov NCT01669291 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
  8. ClinicalTrials.gov NCT05827081 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
  9. ClinicalTrials.gov NCT00528866 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
  10. ClinicalTrials.gov NCT01269125 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
  11. ClinicalTrials.gov NCT00582556 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
  12. ClinicalTrials.gov NCT00329043 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
  13. ClinicalTrials.gov NCT00936390 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
  14. ClinicalTrials.gov NCT02974270 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
  15. ClinicalTrials.gov NCT05304169 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
  16. ClinicalTrials.gov NCT02319837 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
  17. ClinicalTrials.gov NCT04666129 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
  18. ClinicalTrials.gov NCT07142551 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
  19. ClinicalTrials.gov NCT01717053 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
  20. ClinicalTrials.gov NCT01069094 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
  21. ClinicalTrials.gov NCT01078545 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
  22. ClinicalTrials.gov NCT02393482 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
  23. ClinicalTrials.gov NCT02361905 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
  24. ClinicalTrials.gov NCT00992251 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
  25. ClinicalTrials.gov NCT02689921 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
Explore status sources, recent additions, and coverage gaps

Living status brief

What is the current status of Leuprolide?

FDA-approved as Lupron, Eligard, Vobrig and other leuprolide products. The cited Eligard label describes four open-label studies that measured testosterone suppression in men with prostate cancer. Each leuprolide product has its own label and uses.↗↗↗↗↗↗

The cited status sources were checked through August 14, 2026. This answer changes only through the profile’s visible version and correction history.

Evidence present

What records are connected here?

Evidence lanes
4
Source years
32
Drugs@FDA applications
25

These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.

Coverage gaps

What remains unknown or unsupported?

All four evidence lanes appear in this selected collection, but their presence does not establish completeness, agreement, research quality, safety, effectiveness, approval, availability, or suitability.

PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.

Explore the Evidence Map and record counts

Evidence Map v1

What kinds of records connect to Leuprolide?

Compare collection coverage →

This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.

232Selected dated records
235Connected citations
32Populated source years1985–2026
4/4Record lanes present

Registered human studies

Trial composition

51 of 117 selected trial records include at least one phase value; 52 of 117 include a status value in the retained structured contract.

2,924 public history versions connect to 112 of these trial records across 22 submitted years. Open the record-history collection →

PhasesPhase 2 30Phase 3 9Phase 1 8Not applicable 5Phase 4 4
Status at observationCompleted 38Active, not recruiting 7Recruiting 6Not yet recruiting 1

A phase value is unavailable here for 66 selected records; this is not counted as “no phase.”

A status value is unavailable here for 65 selected records; this is not counted as a trial status.

PubMed bibliography

Publication composition

24 of 48 selected PubMed records include attributed title, venue, publication date, and publication-type fields.

Publication typesJournal Article 21Clinical Trial 7Randomized Controlled Trial 5Research Support, Non-U.S. Gov't 5English Abstract 4Case Reports 3Letter 3Clinical Trial, Phase II 2Comment 2Research Support, U.S. Gov't, P.H.S. 2Review 2Comparative Study 1Multicenter Study 1

Bibliography fields unavailable here for 24 selected records; the records remain visible as metadata observations.

Regulatory and publication surfaces

What is structurally connected?

Drugs@FDA applications
25
FDA Federal Register documents
19
DailyMed SPL versions
17
Canonical profile
Published
Profile structured data
Published
Linked dated records
232

Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.

Profile publication history and record counts
Source records by collection · 232 dated records

Research hub

Explore the Leuprolide evidence record

Open all 232 records →
232Dated records
4Evidence types
232Cited public sources
32Source years

Change ledger

Recently changed for Leuprolide

Open all 236 events →

PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.

Record updated

ClinicalTrials.gov record NCT05669664

ClinicalTrials.gov posted a newer version of NCT05669664, with a registry update date of 2026-11-16. This version reports that observation; the earlier retained observation remains available as version 1.

PeptideScanner change date
November 16, 2026
Cited source date
November 16, 2026
Evidence lane
Clinical trials
Profile updated

Leuprolide profile

We re-based this profile on the current Eligard label on DailyMed (SPL version 19, published May 11, 2026), because the generic label cited before is no longer marketed or served, and now describe the studies that label reports. HERO is described only as a trial in which leuprolide was the comparison treatment. Earlier versions remain available.

PeptideScanner change date
November 15, 2026
Evidence lane
Profile
Record added

Leuprolide DailyMed SPL version 1

DailyMed lists Structured Product Labeling version 1 for the reviewed Leuprolide label family with a published date of 2023-09-01. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

PeptideScanner change date
November 15, 2026
Cited source date
September 1, 2023
Evidence lane
Regulatory

Official-source collections

Source records for Leuprolide

Open the full research atlas →
PubMed48

24 with attributed title, venue, publication-date, and type metadata.

  1. Leuprolide acetate, a GnRH agonist, preserves cerebellar integrity and motor coordination in a rat model of hepatic encephalopathy.Physiology & behavior · 2026 10 30
  2. Development and Validation of a Stability-Indicating RS HPLC Method for Leuprolide Acetate and Its Related Substances: Characterization of Degradation Products With LC-MS.Biomedical chromatography : BMC · 2026 Jul
  3. Failure to achieve castration levels in patients using leuprolide acetate in locally advanced prostate cancer.European urology · 2005 11 15
Explore all selected literature →
ClinicalTrials.gov117

2,924 public history versions across these dated registry records; status labels apply only to each cited observation.

  1. NCT05669664Registry update November 16, 2026 · current at observation
  2. NCT05827081Registry update November 13, 2026 · current at observation
  3. NCT07848828Registry update November 2, 2026 · current at observation
Explore all selected trial records →Explore all public record history →
Drugs@FDA25

Original-submission application metadata connected by exact reviewed active-ingredient names.

  1. NDA213225Full FDA chronology · original submission status AP 2026-08-26
  2. ANDA215826Full FDA chronology · original submission status AP 2025-11-13
  3. ANDA217437Full FDA chronology · original submission status AP 2025-06-09
  4. ANDA217957Full FDA chronology · original submission status AP 2024-10-17
  5. ANDA215336Full FDA chronology · original submission status AP 2022-10-28
Explore all selected FDA applications →Explore 424 dated submissions and 450 documents for Leuprolide →
FDA enforcement reports6

Recall-enforcement metadata connected only through exact application numbers already mapped to this reviewed profile.

  1. D-1178-2023Class III · report date 2023-10-04
  2. D-1287-2014Class II · report date 2014-05-07
  3. D-1288-2014Class II · report date 2014-05-07
  4. D-1289-2014Class II · report date 2014-05-07
  5. D-1290-2014Class II · report date 2014-05-07
Explore all exact FDA enforcement reports →
DailyMed SPL history17

Version metadata and exact historical ZIP receipts for the reviewed label family, without reproducing or interpreting label text.

  1. SPL version 10Published 2026-07-06 · ZIP SHA-256 86f3963f5e8c…
  2. SPL version 19Published 2026-05-11 · ZIP SHA-256 e08a1c26251d…
  3. SPL version 9Published 2025-12-29 · ZIP SHA-256 c979d44225f4…
  4. SPL version 7Published 2025-04-28 · ZIP SHA-256 282a2d471703…
  5. SPL version 18Published 2025-02-28 · ZIP SHA-256 67f61e0778e9…
Explore all DailyMed label versions →

Evidence types

Coverage by source year

Selected records span April 9, 1985 to November 16, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.

Continue exploring

Profiles with overlapping source-year coverage

Open the research atlas →

These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.

Organizations and trial records named in cited sources

Organizations named in cited records

  • U.S. National Library of Medicine1
  • U.S. Food and Drug Administration2,7
Dated updates connected to this profile · 232

Updates connected to this profile

Open the full cross-source timeline →
  1. Clinical trials

    ClinicalTrials.gov record NCT05669664↗

    PeptideScanner retained ClinicalTrials.gov record NCT05669664 at 2026-11-16T13:28:59.838Z. Its registry update date was 2026-11-16, and PeptideScanner's reviewed identity mapping was leuprolide.↗

  2. Clinical trials

    ClinicalTrials.gov record NCT05827081↗

    PeptideScanner retained ClinicalTrials.gov record NCT05827081 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-13, and PeptideScanner's reviewed identity mapping was leuprolide.↗

  3. Literature metadata

    Leuprolide acetate, a GnRH agonist, preserves cerebellar integrity and motor coordination in a rat model of hepatic encephalopathy.↗

    PubMed lists PMID 42962871 in Physiology & behavior as Journal Article, with publication-date metadata of 2026-10-30 (day precision). PeptideScanner associated the retained record with the identity slug leuprolide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  4. Clinical trials

    ClinicalTrials.gov record NCT07848828↗

    PeptideScanner retained ClinicalTrials.gov record NCT07848828 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-02, and PeptideScanner's reviewed identity mapping was leuprolide.↗

  5. Clinical trials

    ClinicalTrials.gov record NCT01674140↗

    PeptideScanner retained ClinicalTrials.gov record NCT01674140 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-23, and PeptideScanner's reviewed identity mapping was leuprolide.↗

  6. Clinical trials

    ClinicalTrials.gov record NCT07801664↗

    PeptideScanner retained ClinicalTrials.gov record NCT07801664 at 2026-09-09T19:17:17.074Z. Its registry update date was 2026-09-03, and PeptideScanner's reviewed identity mapping was leuprolide.↗

  7. Regulatory

    Drugs@FDA application NDA213225↗

    The official Drugs@FDA dataset lists original submission 1 for NDA 213225 with status AP dated 2026-08-26, and names leuprolide acetate among the application record's active ingredients.↗

  8. Regulatory

    Federal Register notice 2026-17222↗

    The Federal Register published notice 2026-17222, attributed to FDA and its parent HHS department, on 2026-08-24. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Leuprolide and Octreotide.↗

  9. Clinical trials

    ClinicalTrials.gov record NCT07596212↗

    PeptideScanner retained ClinicalTrials.gov record NCT07596212 at 2026-09-09T19:17:17.112Z. Its registry update date was 2026-08-24, and PeptideScanner's reviewed identity mapping was leuprolide.↗

  10. Clinical trials

    ClinicalTrials.gov record NCT07455903↗

    PeptideScanner retained ClinicalTrials.gov record NCT07455903 at 2026-08-13T05:52:27.015Z. Its registry update date was 2026-08-06, and PeptideScanner's reviewed identity mapping was leuprolide.↗

  11. Literature metadata

    PubMed record PMID 39177865↗

    PeptideScanner retained PubMed bibliographic metadata for PMID 39177865 at 2026-08-10T10:49:06.892Z. PubMed recorded a metadata revision date of 2026-08-04 and an Entrez history date of 2024-08-23. PeptideScanner associated this retained record with the identity slug leuprolide. These dates describe PubMed metadata history, not the article's original publication date.↗

  12. Literature metadata

    PubMed record PMID 41824265↗

    PeptideScanner retained PubMed bibliographic metadata for PMID 41824265 at 2026-08-10T10:49:08.794Z. PubMed recorded a metadata revision date of 2026-08-03 and an Entrez history date of 2026-03-13. PeptideScanner associated this retained record with the identity slug leuprolide. These dates describe PubMed metadata history, not the article's original publication date.↗

Citations

Sources

Coverage and sources →

Numbered markers in the text point here. Each link opens the original public record.

  1. 1
    ELIGARD (leuprolide acetate) injection, suspension, extended release · SPL version 19 · published 2026-05-11 ↗

    DailyMed · U.S. National Library of Medicine · Official source · Source checked November 15, 2026

  2. 2
    Drugs@FDA application NDA019010 · original submission status AP · 1985-04-09 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

  3. 3
    Drugs@FDA application NDA019732 · original submission status AP · 1989-01-26 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

  4. 4
    Drugs@FDA application NDA020263 · original submission status AP · 1993-04-16 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

  5. 5
    Drugs@FDA application NDA021343 · original submission status AP · 2002-01-23 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

  6. 6
    Drugs@FDA application NDA213150 · original submission status AP · 2020-05-01 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

  7. 7
    Vobrig (leuprolide acetate): NDA 213225 approval letter, August 26, 2026 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

  8. 8
    Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer (HERO, 2020) · PMID 32469183 ↗

    The New England Journal of Medicine · Official source · Source checked November 14, 2026

  9. 9
    Drugs@FDA application NDA213225 · original submission status AP · 2026-08-26 · dataset 2026-11-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked November 15, 2026